Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 24

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 24
---
ances or approvals more rapidly than we can or selling
competitive products at prices lower than ours. If medical research were to lead to the discovery of alternative therapies or technologies
that improve or cure tissue regeneration as an alternative to surgery, the use of pharmaceuticals or breakthrough bio-technological innovations
or therapies, our profitability could suffer through a reduction in sales or a loss in market share to a competitor. The discovery of
methods of prevention or the development of other alternatives to tissue repair therapies could result in decreased demand for our product
and, accordingly, could have a material adverse effect on our business, financial condition and results of operations. Many of our current
and potential competitors have substantially greater sales and financial resources than we do. These competitors may also have more established
distribution networks, a broader offering of products, entrenched relationships with surgeons and distributors or greater experience
in launching, marketing, distributing and selling products or treatment alternatives.

We also compete with our
competitors to engage the services of independent sales agents, both those presently working with us and those with whom we hope to work
with as we expand. In addition, we compete with our competitors in acquiring technologies and technology licenses complementary to our
products or procedures or advantageous to our business. If we are unable to compete successfully against our existing or potential competitors,
our business, financial condition and results of operations may be adversely affected, and we may not be able to grow at our expected
rate, if at all. See “Business – Competition” below.

We expect to derive most of our revenues from the sales of our GelrinC. Our inability to successfully commercialize this product candidate or any subsequent decline in demand for this product candidate, could severely harm our ability to generate revenues.

We are currently dependent
on the successful commercialization of GelrinC to generate revenues. As a result, factors adversely affecting our ability to successfully
commercialize, or the pricing of or demand for, this product could have a material adverse effect on our financial condition and results
of operations. If we are unable to successfully commercialize or create market demand for GelrinC, we will have limited ability to generate
revenues.

Furthermore, we may be vulnerable
to fluctuations in demand for GelrinC. Such fluctuations in demand may be due to many factors, many of which are beyond our control,
including, among others:

| ● | market acceptance of a                                                      
 new product, including healthcare professionals’ and patients’ preferences; |

<div align='center'>20</div>

| ● |